BioCryst to Report Third Quarter 2023 Financial Results on November 2
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst
Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, November 2, 2023.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological
pathway of the disease. Oral, once-daily ORLADEYO (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple
targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB (peramivir injection) is approved in the U.S. and multiple global markets, with
post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Lesen Sie auch
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com